Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

We want to host all sorts of things—pop up events around food, golf fittings, special musical guests, all the way to charity tournaments and networking events. There’s so much potential for ...

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158. ...

TaylorMade TP5 and TP5x TRK-R golf balls are available now for $64.99 a dozen on TaylorMadeGolf.com, and will be available in fitting bays at certified TaylorMade fitting locations. Want to ...

10x Genomics Inc (NASDAQ:TXG) launched major new products across all three platforms, receiving a tremendous customer response. The company introduced new products in the single-cell portfolio ...

10x Genomics Price Performance Shares of TXG opened at $12.31 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85. The stock’s fifty day moving average ...

Volkswagen's duo of hot hatches just got a little more expensive. The automaker released pricing figures for the 2025 Golf GTI and Golf R, both of which see increases compared with their 2024 ...

In trading on Monday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $11.8955 per share. By comparison ...

TXG opened at $12.31 on Thursday. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -8.05 and a beta of 1.85. 10x Genomics has a 1 year low of $10.80 and a 1 year high of ...